Protections for clinical trials in low and middle income countries need strengthening not weakeningBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g4516 (Published 08 July 2014) Cite this as: BMJ 2014;349:g4516
In this Analysis article by Rafael Dal-Ré and colleagues (BMJ 2014;349:g4254, doi:10.1136/bmj.g4254), we failed to take in two corrections at the proof stage. In the second paragraph of the section on likelihood of benefit, the fifth sentence should have read: “Thirty per cent of all new medicines starting phase III fail to conclude it successfully. . .” In table 2, the second row should be labelled “Cycle times” not “Average cycle time.” Lastly, the authors would also like to point out that the median number of participants in the table refers to all three trial phases.
Cite this as: BMJ 2014;349:g4516